Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 475 participants.
Also called NCT04400799
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 475 participants
- Sponsor
- Registry
-
NCT04400799
-
- Other papers using this trial's data
- Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany, Switzerland
- Registry status
- Terminated
Technical summary
Registry record NCT04400799. Randomized; no masking; primary purpose treatment. Start 2020-06-15 (actual); primary completion 2022-02-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19
- Condition
- COVID-19
- Condition
- Pulmonary Embolism, Deep Vein Thrombosis
- Intervention (Drug)
- Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml
- Lead sponsor
- University of Zurich
- Collaborator
- Insel Gruppe AG, University Hospital Bern
- Collaborator
- University Hospital, Geneva
- Collaborator
- Centre Hospitalier Universitaire Vaudois
- Collaborator
- University Hospital, Basel, Switzerland
- Collaborator
- Oncology Institute of Southern Switzerland
- Collaborator
- Clinica Luganese Moncucco
- Collaborator
- University Hospital Freiburg
- Collaborator
- Mainz University
Record details
- Record id
cardio:ct-nct04400799- Content hash
5417755244b3126bf906d97abc439c878b4ac510077ad6df4702a1095c7e75f6